AAMU
MDGL icon

Amundi Asset Management US’s Madrigal Pharmaceuticals MDGL Stock Holding History

Amundi Asset Management US’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed -$11K – 1632
2020
Q2 		$11K Buy
+100
New +$9.83K ﹤0.01% 1530
2018
Q1 		– Sell
-400
Closed -$37K – 1572
2017
Q4 		$37K Buy
+400
New +$22.8K ﹤0.01% 1530

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Amundi Asset Management US's MDGL Position: Q3 2020 in Review

Amundi Asset Management US sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2020, closing a stake of 100 shares — an estimated $11K sold.

Amundi Asset Management US first reported a position in MDGL in Q4 2017 and held it in 2 quarters. The position peaked at $37K in Q4 2017. 124 funds tracked by Wall St. Rank hold MDGL as of Q3 2020.

  • Amundi Asset Management US reported no remaining Madrigal Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Amundi Asset Management US sold 100 Madrigal Pharmaceuticals shares in Q3 2020, an estimated $11K.
  • Amundi Asset Management US first reported a position in Madrigal Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Amundi Asset Management US's Madrigal Pharmaceuticals position peaked at $37K in Q4 2017.
  • 124 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2020.

Based on Amundi Asset Management US's 13F filing for Q3 2020, filed 16 Nov 2020.